Drug is the latest addition in the firm's continued expansion of limited distribution offerings
GREENSBORO, N.C., June 16, 2023 /PRNewswire-PRWeb/ -- AvevoRx, a national, independent provider of specialty infusion pharmacy services, has announced a limited distribution agreement for Gammaplex®, an immune globulin (IG) product from Bio Products Laboratory (BPL). AvevoRx currently stocks Gammaplex and is dispensing to qualified patients.
"Our top priority as a company is ensuring our patients have safe and streamlined access to the treatments they need. Expanding our portfolio helps us meet that need and adding Gammaplex to the mix is a great step for us," said Eric Hill, co-founder of AvevoRx. "We appreciate the trust that partners like BPL have in us to deliver that care."
"Our experience with Gammaplex, and its high degree of tolerability, gives us more treatment options for our IG patients and prescribers," said Justin Dent, National Director of Pharmacy Operations for AvevoRx. "Additionally, having both a 5- and 10-percent concentration gives our clinicians more options to manage side effects and tailor each patient's therapy to their specific needs."
Gammaplex is an IG product for patients with primary humoral immunodeficiencies (PI), a group of disorders that limit the body's ability to produce antibodies and fight infections. It harnesses human antibodies, derived primarily from human plasma, to help boost the immune system and prevent infections. Multiple IG products are available in the U.S. The agreement with BPI allows AvevoRx to dispense a larger portfolio of IVIG products.
Gammaplex is a registered trademark of Bio Products Laboratory Limited, a Kedrion company.
Visit AvevoRx.com for more information.
About AvevoRx
AvevoRx is a bespoke, independent provider of specialty infusion pharmacy services. The company focuses on the highest-quality, personalized care customized to patients facing various complex, chronic disorders. Treatments are made available via specialized pharmacy locations, field nurses, and additional support staff throughout the United States. AvevoRx also provides acute infusion therapies for patients with short-term therapeutic needs on a regional basis. Privately held, the company was founded in 2021 by a small group of industry veterans with a combined experience of more than 130 years. AvevoRx is headquartered in North Carolina. To learn more, visit http://www.AvevoRx.com or follow us on Instagram or LinkedIn.
Media Contact
Victoria Seremeta, AvevoRx, 1 5162861950, victoria@howleygroupllc.com
SOURCE AvevoRx
Share this article